Workgroup 2: Staging and reporting of prostate cancer--Sampling of the radical prostatectomy specimen
โ Scribed by Wael A. Sakr; Thomas M. Wheeler; Michael Blute; Miklos Bodo; Rocio Calle-Rodrigue; Donald Earl Henson; Fathollah K. Mostofi; Jennifer Seiffert; Kirk Wojno; Horst Zincke
- Publisher
- John Wiley and Sons
- Year
- 1996
- Tongue
- English
- Weight
- 216 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
he following document represents recommendations pertinent T only to a pathologic TNM staging system. This summary is not intended to debate the prognostic importance of any of the morphologic parameters listed (volume, multicentricity, zonal origin, etc.).
๐ SIMILAR VOLUMES
Prostate cancer is the most commonly diagnosed malignancy among men in the United States. Radical prostatectomy has been the gold standard for treating clinically localized prostate cancer. Its morbidity and disease-control capabilities have been well studied. At 10 years after surgery, 50% to 70% o
## Background: The number of prostate cancer patients treated by radical prostatectomy has increased. different data sources have yielded various estimates of the outcomes of this treatment and the need for additional therapy. to provide additional perspective on these issues, the american college
One hundred consecutive men with adenocarcinoma of the prostate, treated by modified pelvic lymphadenectomy and radical retropubic prostatectomy, were evaluated, comparing DNA ploidy as determined by flow cytometry to surgical tumor stage (pT), preoperative prostatic specific antigen (PSA), Gleason